Instituto Médico Río Cuarto
Institución privada con internaciónInstituto Médico Río Cuarto
Hipólito Yrigoyen 1020, X5800 Río Cuarto, Córdoba, Argentina
Websitehttp://www.imrc.com.ar
Select an option
I am a doctor
I am a sponsor
Specializations
Onco-hematología
Insuficiencia cardiaca
Cardiovascular
Virus sincitial respiratorio
Infección del tracto respiratorio
Cáncer urotelial
Fibrosis pulmonar idiopática
Bronquiectasia por fibrosis no quística
Fibrosis pulmonar
Hipertensión arterial pulmonar
Covid-19
Our team
Medical staff
Alejo Lingua
Sebastián Etchevers
Ignacio Magri
Open studies
Lung cancer
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] - MK-2870-023 - Merck Sharp & Dohme LLCSee more
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% - RELATIVITY1093 - Bristol-Myers SquibbSee more
Obesity
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and CompanySee more
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight - ATTAIN-OSA - Eli Lilly and CompanySee more
Pulmonary fibrosis
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease - Moonscape - Genentech, Inc.See more
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) - TETON-PPF - United TherapeuticsSee more
Rare diseases
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease - Moonscape - Genentech, Inc.See more
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) - ATHENA-SSc-ILD - Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)See more
Breast Cancer
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and CompanySee more
Head and neck cancer
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone - Boehringer IngelheimSee more
Interstitial Lung Disease
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) - ATHENA-SSc-ILD - Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)See more
Renal disease
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and CompanySee more
Sleep disorders
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight - ATTAIN-OSA - Eli Lilly and CompanySee more
